Neurocognitive impairment and evidence-based treatment options in Bipolar disorder
- PMID: 32983247
- PMCID: PMC7513501
- DOI: 10.1186/s12991-020-00304-4
Neurocognitive impairment and evidence-based treatment options in Bipolar disorder
Abstract
Background: The current paper briefly summarizes the literature on the neurocognitive deficit and its treatment in BD patients.
Methods: The material was chosen on the basis of previous systematic reviews the author has taken part in.
Results: The data so far suggest that the deficit is qualitatively similar but quantitatively milder in comparison to schizophrenia, it is present already since the first episode, is weakly related to mood symptoms and somewhat stronger to psychotic symptoms, it probably determines much of the disability and treatment is problematic. This deficit is also present during periods of euthymia. The possible adverse effect of psychotropic medication is rather small if any at all and is confounded by the specific clinical symptoms, for which medication is used for their treatment. This is especially true concerning antipsychotics and psychotic symptoms. The origin and the etiopathogenesis of the core neurocognitive impairment remain elusive. The presence of a neurodegenerative and of a neurodevelopmental component has both data in favor and against and they are both the focus of debate.
Conclusions: Treatment of the neurocognitive deficit and restoration of functioning is problematic. The data are limited and treatment options are few and with a weak overall effect. Pharmacological treatments, ECT and rTMS present some hard data, while the literature is inconclusive concerning psychotherapeutic interventions.
Keywords: Bipolar disorder; Cognitive disorder; Cognitive remediation; Functional remediation, treatment; Neurocognitive disorder.
© The Author(s) 2020.
Conflict of interest statement
Competing interestsKNF has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Pfizer, the Pfizer Foundation, Sanofi-Aventis, Servier, Shire and others.
Figures

Similar articles
-
Neurocognition in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia.J Affect Disord. 2017 Nov;222:169-176. doi: 10.1016/j.jad.2017.07.014. Epub 2017 Jul 8. J Affect Disord. 2017. PMID: 28709024
-
The neurocognitive functioning in bipolar disorder: a systematic review of data.Ann Gen Psychiatry. 2015 Dec 1;14:42. doi: 10.1186/s12991-015-0081-z. eCollection 2015. Ann Gen Psychiatry. 2015. PMID: 26628905 Free PMC article.
-
Cognitive deficits in bipolar disorders: Implications for emotion.Clin Psychol Rev. 2018 Feb;59:126-136. doi: 10.1016/j.cpr.2017.11.006. Epub 2017 Nov 21. Clin Psychol Rev. 2018. PMID: 29195773 Free PMC article. Review.
-
Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy.CNS Drugs. 2007;21(12):971-81. doi: 10.2165/00023210-200721120-00002. CNS Drugs. 2007. PMID: 18020478 Review.
-
Psychosocial functioning in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia.J Affect Disord. 2018 Mar 15;229:177-185. doi: 10.1016/j.jad.2017.12.094. Epub 2018 Jan 2. J Affect Disord. 2018. PMID: 29316520
Cited by
-
Calcium imaging reveals depressive- and manic-phase-specific brain neural activity patterns in a murine model of bipolar disorder: a pilot study.Transl Psychiatry. 2021 Dec 7;11(1):619. doi: 10.1038/s41398-021-01750-8. Transl Psychiatry. 2021. PMID: 34876553 Free PMC article.
-
The Big Five as Predictors of Cognitive Function in Individuals with Bipolar Disorder.Brain Sci. 2023 May 8;13(5):773. doi: 10.3390/brainsci13050773. Brain Sci. 2023. PMID: 37239245 Free PMC article.
-
Factors Associated With Insight Toward Illness in Patients With Bipolar Disorder Type 1 in Manic Episodes.Alpha Psychiatry. 2025 Jun 24;26(3):44176. doi: 10.31083/AP44176. eCollection 2025 Jun. Alpha Psychiatry. 2025. PMID: 40630883 Free PMC article.
-
Electroconvulsive therapy combined with lithium developed reversible pure anomic aphasia: a case report.BMC Psychiatry. 2022 Oct 27;22(1):663. doi: 10.1186/s12888-022-04323-1. BMC Psychiatry. 2022. PMID: 36303177 Free PMC article.
-
Association of Lithium and Second-Generation Antipsychotics with Neurocognition in Youth with Bipolar Disorder.J Child Adolesc Psychopharmacol. 2022 Feb;32(1):61-69. doi: 10.1089/cap.2021.0093. Epub 2022 Jan 25. J Child Adolesc Psychopharmacol. 2022. PMID: 35085001 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources